156 related articles for article (PubMed ID: 26956920)
41. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration.
Euller-Ziegler L; Vélicitat P; Bluhmki E; Türck D; Scheuerer S; Combe B
Inflamm Res; 2001 Mar; 50 Suppl 1():S5-9. PubMed ID: 11339521
[TBL] [Abstract][Full Text] [Related]
42. [Percutaneous absorption of meloxicam patches in hairless mouse].
Gao QZ; Yang LY; Ding PT; He ZG
Yao Xue Xue Bao; 2007 Dec; 42(12):1320-2. PubMed ID: 18338648
[TBL] [Abstract][Full Text] [Related]
43. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
[TBL] [Abstract][Full Text] [Related]
44. Meloxicam β-cyclodextrin transdermal gel: physicochemical characterization and in vitro dissolution and diffusion studies.
Rasool BK; Gareeb RH; Fahmy SA; Rasool AA
Curr Drug Deliv; 2011 Jul; 8(4):381-91. PubMed ID: 21453259
[TBL] [Abstract][Full Text] [Related]
45. The effect of mixed-solvent and terpenes on percutaneous absorption of meloxicam gel.
Chang JS; Tsai YH; Wu PC; Huang YB
Drug Dev Ind Pharm; 2007 Sep; 33(9):984-9. PubMed ID: 17891585
[TBL] [Abstract][Full Text] [Related]
46. Influence of ion-pairing and chemical enhancers on the transdermal delivery of meloxicam.
Zhang JY; Fang L; Tan Z; Wu J; He ZG
Drug Dev Ind Pharm; 2009 Jun; 35(6):663-70. PubMed ID: 19259875
[TBL] [Abstract][Full Text] [Related]
47. A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects.
Li Q; Chen F; Liu Y; Yu S; Gai X; Ye M; Yang X; Pan W
Int J Nanomedicine; 2018; 13():4711-4725. PubMed ID: 30154656
[TBL] [Abstract][Full Text] [Related]
48. Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain--biopharmaceutic and pharmacokinetic challenges.
Srinivas NR
Eur J Drug Metab Pharmacokinet; 2009; 34(1):7-10. PubMed ID: 19462922
[TBL] [Abstract][Full Text] [Related]
49. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics.
Cheney ML; Weyna DR; Shan N; Hanna M; Wojtas L; Zaworotko MJ
J Pharm Sci; 2011 Jun; 100(6):2172-81. PubMed ID: 21491441
[TBL] [Abstract][Full Text] [Related]
50. Density functional calculations on meloxicam-beta-cyclodextrin inclusion complexes.
Snor W; Liedl E; Weiss-Greiler P; Viernstein H; Wolschann P
Int J Pharm; 2009 Nov; 381(2):146-52. PubMed ID: 19446616
[TBL] [Abstract][Full Text] [Related]
51. Topical delivery of drugs for the effective treatment of fungal infections of skin.
Akhtar N; Verma A; Pathak K
Curr Pharm Des; 2015; 21(20):2892-913. PubMed ID: 25925110
[TBL] [Abstract][Full Text] [Related]
52. Ibuprofen delivery into and through the skin from novel oxidized cellulose-based gels and conventional topical formulations.
Celebi D; Guy RH; Edler KJ; Scott JL
Int J Pharm; 2016 Nov; 514(1):238-243. PubMed ID: 27863667
[TBL] [Abstract][Full Text] [Related]
53. The effect of the composition of a fixed dose combination on bioequivalence results.
Šalandová J; Franc A; Hofmann J; Dumicic A; Kukačková L; Červená T; Beránek J; Srbek J; Repický A; Vladovičová B; Vetchý D
Int J Pharm; 2018 Jul; 546(1-2):235-246. PubMed ID: 29758343
[TBL] [Abstract][Full Text] [Related]
54. Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations.
Hanft G; Türck D; Scheuerer S; Sigmund R
Inflamm Res; 2001 Mar; 50 Suppl 1():S35-7. PubMed ID: 11339520
[TBL] [Abstract][Full Text] [Related]
55. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema.
Göksel O; Aydin O; Misirligil Z; Demirel YS; Bavbek S
J Dermatol; 2010 Nov; 37(11):973-9. PubMed ID: 21039786
[TBL] [Abstract][Full Text] [Related]
56. Particle engineering/different film approaches for earlier absorption of meloxicam.
Farid M; El-Setouhy DA; El-Nabarawi MA; El-Bayomi T
Drug Deliv; 2016 Sep; 23(7):2309-2317. PubMed ID: 25431841
[TBL] [Abstract][Full Text] [Related]
57. Low density multiparticulate system for pulsatile release of meloxicam.
Sharma S; Pawar A
Int J Pharm; 2006 Apr; 313(1-2):150-8. PubMed ID: 16540268
[TBL] [Abstract][Full Text] [Related]
58. Effects of penetration enhancers on in vitro permeability of meloxicam gels.
Jantharaprapap R; Stagni G
Int J Pharm; 2007 Oct; 343(1-2):26-33. PubMed ID: 17531412
[TBL] [Abstract][Full Text] [Related]
59. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.
Ruperto N; Nikishina I; Pachanov ED; Shachbazian Y; Prieur AM; Mouy R; Joos R; Zulian F; Schwarz R; Artamonova V; Emminger W; Bandeira M; Buoncompagni A; Foeldvari I; Falcini F; Baildam E; Kone-Paut I; Alessio M; Gerloni V; Lenhardt A; Martini A; Hanft G; Sigmund R; Simianer S;
Arthritis Rheum; 2005 Feb; 52(2):563-72. PubMed ID: 15692986
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of alternative strategies to optimize ketorolac transdermal delivery.
Puglia C; Filosa R; Peduto A; de Caprariis P; Rizza L; Bonina F; Blasi P
AAPS PharmSciTech; 2006 Aug; 7(3):64. PubMed ID: 17025245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
